| All patients (355) | Survivors (248) | Nonsurvivors (107) | p Value |
---|---|---|---|---|
Age (years) | 68 (57-74) | 68 (57–74) | 70 (58–76) | 0.27 |
Sex | Â | Â | Â | 0.197 |
 Female | 151 (42.54%) | 111 (44.8%) | 40 (37.4%) |  |
 Male | 204 (57.46%) | 137 (55.2%) | 67 (62.6%) |  |
SAPS II | 53 (45–62) | 51 (43–58) | 57 (49–69) | < 0.001 |
SOFA D1 | 11 (9–13) | 10 (8–12) | 12 (11–14) | < 0.001 |
Murray Lung Injury Score | 3 (1–5) | 3 (1–5) | 4 (3–6) | < 0.001 |
Type of admission | Â | Â | Â | 0.052 |
 Surgical | 264 (74.8%) | 192 (77.7%) | 77 (67.9%) |  |
 Medical | 89 (25.2%) | 55 (22.3%) | 34 (32.1%) |  |
Onset of septic shock | Â | Â | Â | 0.08 |
 Extra ICU | 265 (75.07%) | 179 (72.5%) | 86 (81.1%) |  |
 Intra-ICU | 88 (24.93%) | 68 (27.5%) | 20 (18.9%) |  |
Primary site of infection |  |  |  | < 0.001 |
 Abdomen | 198 (55.77%) | 150 (60.5%) | 48 (44.9%) | p = 0.006 |
 Skin | 27 (7.61%) | 15 (6.0%) | 12 (11.2%) |  |
 Bloodstream | 11 (3.1%) | 6 (2.4%) | 5 (4.7%) |  |
 Not identified | 19 (5.35%) | 11 (4.4%) | 8 (7.5%) |  |
 Lungs | 64 (18.03%) | 33 (13.3%) | 31 (29.0%) | p < 0.001 |
 Urinary tract | 31 (8.73%) | 28 (11.3%) | 3 (2.8%) | p = 0.018 |
 Central nervous system | 5 (1.41%) | 5 (2.0%) | 0 (0.0%) |  |
Adequacy of antimicrobial therapy | Â | Â | Â | 0.26 |
 No | 45 (17%) | 28 (15%) | 17 (21%) |  |
 Yes | 219 (83%) | 155 (84%) | 64 (79%) |  |
MDR bacteria | Â | Â | Â | 0.01 |
 Absent | 277 (85.76%) | 202 (89%) | 75 (78.1%) |  |
 Present | 46 (14.24%) | 25 (11%) | 21 (21.9%) |  |
Fungi | Â | Â | Â | 0.014 |
 Absent | 262 (81.11%) | 192 (84.6%) | 70 (72.9%) |  |
 Present | 61 (18.89%) | 35 (15.4%) | 26 (27.1%) |  |
Length of stay (days) | 10 (6–17) | 11 (6–17) | 9 (3–17) | 0.019 |
Year of enrollment | 2011 (2008–2013) | 2011 (2008–2013) | 2011 (2008–2013) | 0.57 |
Delay in ivIgGAM administration from admission in ICU (hours) | 12 (3–39) | 12 (3–33) | 14 (3–66) | 0.22 |